Evidence map›Paper›PMID 42022294›Full record

ReviewFrontiers in dementia2026

AI-driven magnetoencephalography biomarkers in dementia risk prediction: current evidence, challenges and future perspectives.

Electra Chatzidimitriou, Charis Styliadis, Katherine P Rankin, Despina Moraitou, Panagiotis Ioannidis, Panagiotis D Bamidis

Abstract readReview
In one paragraph

Review in Frontiers in dementia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Electra ChatzidimitriouLaboratory of Medical Physics and Digital Innovation, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki (AUTh), Thessaloniki, Greece.
Charis StyliadisLaboratory of Medical Physics and Digital Innovation, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki (AUTh), Thessaloniki, Greece.
Katherine P RankinDepartment of Neurology, The Edward and Pearl Fein Memory and Aging Center, University of California, San Francisco, San Francisco, CA, United States.
Despina MoraitouDepartment of Cognition, Brain and Behavior, Faculty of Philosophy, School of Psychology, Aristotle University of Thessaloniki (AUTh), Thessaloniki, Greece.
Panagiotis Ioannidis2nd Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki (AUTh), Thessaloniki, Greece.
Panagiotis D BamidisLaboratory of Medical Physics and Digital Innovation, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki (AUTh), Thessaloniki, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Dementia imposes a substantial global healthcare burden, with rising prevalence and limited disease-modifying treatments. Early identification of at-risk individuals is critical for timely intervention and care planning. Magnetoencephalography (MEG) provides high-temporal-resolution measurements of neuronal activity, capturing subtle functional alterations that precede clinical symptoms. Artificial intelligence (AI), particularly machine learning (ML), can leverage MEG's rich spatiotemporal information to enhance diagnostic accuracy and dementia risk prediction. This scoping review synthesizes current evidence on AI-driven MEG analysis for the classification, prediction, and prognosis of MCI and dementia, focusing on methodological approaches, predictive performance, and translational potential. Methods: A systematic PubMed-MEDLINE search identified studies published between January 2015 and October 2025, capturing the last decade's rapid evolution of AI methodologies and their integration with neurophysiological research. Search terms combined MEG, AI, and ML with cognitive impairment and dementia. Eligible studies were peer-reviewed original research, involved human participants, employed MEG, and applied AI algorithms for classification or prediction. Extracted data included study population characteristics, MEG features, ML models, predictive biomarkers, and performance metrics. Results: Fourteen studies met eligibility criteria, covering populations from healthy controls to individuals with subjective cognitive decline, MCI, AD, and other dementias. MEG systems varied, with most studies employing 306-channel whole-head systems. ML algorithms ranged from traditional approaches, such as support vector machines and random forests, to deep learning architectures, including convolutional neural networks. Reported classification accuracies ranged from moderate (~60%) to high, with several studies achieving over 80% in distinguishing diagnostic categories or predicting MCI-to-AD progression. Key biomarkers included alterations in frequency-specific oscillatory activity, functional connectivity patterns, and large-scale network dynamics. Multimodal approaches integrating MEG with structural neuroimaging further improved predictive performance. Discussion/conclusions: Despite heterogeneity across study designs, AI-driven MEG analyses hold significant translational potential for early, non-invasive dementia prediction, enhancing diagnostic and prognostic accuracy. Advancing clinical translation will require standardized preprocessing pipelines, larger multicenter cohorts, and explainable AI frameworks. Future research should leverage next-generation MEG technologies, such as optically pumped magnetometers, to capture brain dynamics in ecologically valid, real-world scenarios. Integrating these data with AI-driven multimodal biomarkers will improve individualized risk prediction, early diagnosis, and therapeutic decision-making in dementia.

Indexed as

artificial intelligencedementiafunctional neuroimagingmachine learningMCIMEGneurophysiological biomarkersrisk prediction

Identifiers

PMID42022294
PMCPMC13095543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.